@inproceedings{
delong2023neurosymbolic,
title={Neurosymbolic {AI} Reveals Biases and Limitations in {ML}-Driven Drug Discovery},
author={Lauren DeLong and Yojana Gadiya and Jacques D. Fleuriot and Daniel Domingo-Fern{\'a}ndez},
booktitle={NeurIPS 2023 Workshop on New Frontiers of AI for Drug Discovery and Development},
year={2023},
url={https://openreview.net/forum?id=KWWbS5yVtl}
}
Recently, several machine learning approaches have aided drug discovery by identifying promising candidates and predicting potential indications. However, understanding the ways in which drugs achieve their therapeutic effects, otherwise known as their mechanisms-of-action (MoA), is important for understanding potency, side effects, and interactions with various tissue types, among other things. We leveraged and improved the interpretability of a neurosymbolic reinforcement learning method in an attempt to reveal MoAs. While doing so, we observed that our findings raised several concerns with the reasoning process. Specifically, we debate situations in which patterns following a "guilt-by-association" trend are useful for predictions regarding novel compounds. We present our results to facilitate discussion about how generalizable ML-based models are to the drug discovery process as well as how important interpretability can be to such models.
Neurosymbolic AI Reveals Biases and Limitations in ML-Driven Drug Discovery
Lauren DeLong Yojana Gadiya Jacques D. Fleuriot Daniel Domingo-Fernández